Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.

Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib. Curr Med Res Opin. 2017 Jul 18;:1-27 Authors: Ko PS, Yu YB, Liu YC, Wu YT, Hung MH, Gau JP, Liu CJ, Hsiao LT, Chen PM, Chiou TJ, Liu CY, Liu JH Abstract OBJECTIVES: We aimed to examine the prognostic value of anemia for the diagnosis of chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib. METHODS: One hundred fifty-four CML-CP patients were enrolled. The influences of moderate anemia with hemoglobin (Hb)
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

Conclusion: Moderate anemia is a common concomitant symptom in CML-CP patients and is associated with high-risk CML, but its occurrence does not affect the survival of CML-CP patients in TKI era. PMID: 32432512 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
In this study, we evaluated the efficacy and tolerability of IM in children and adolescents with CML. We investigated 21 patients under 18 years of age with newly diagnosed CML and treated with IM in Children's Hospital of Chongqing Medical University between May 2014 and February 2018. The disease was staged according to the European LeukemiaNet criteria and the IM dose was determined based on the disease stage. Cumulative responses and survival probabilities were estimated according to the Kaplan–Meier method. The estimated complete hematologic response rate of chronic phase-chronic myeloid leukemia (CML-CP) was ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
We report here the case of a patient with chronic myeloid leukemia (CML) in the chronic phase who was diagnosed 1 year after receiving a diagnosis of autoimmune hemolytic anemia (AIHA). The objective was to assess if the CML patient progressed from AIHA and explore the underlying factors of the poor outcome after the achievement of molecular complete remission (MCR). Patient concerns: A patient with AIHA underwent splenectomy because of poor response to immune inhibitors. The spleen biopsy showed reactive hyperplasia. Diagnosis: The patient was diagnosed with CML because of over-expression of the BCR-ABL (P210) gene ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
This study closed early due to accrual and is registered with the UMIN Clinical Trials Registry (UMIN000011099).FindingsBetween Sept 20, 2013 and July 12, 2016, 68 patients who had a deep molecular response after receiving first-line dasatinib for at least 24 months were enrolled and assigned to the consolidation phase. Nine patients were excluded during the consolidation phase and one patient was excluded after study completion because of meeting exclusion criteria. 58 patients discontinued dasatinib and were assessed. 32 (55%) of 58 patients had treatment-free remission at 6 months after dasatinib discontinuation, and me...
Source: The Lancet Haematology - Category: Hematology Source Type: research
We report a novel case in which hydroxyurea hyperpigmentation is associated with iron deposition.
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
We report a novel case in which hydroxyurea hyperpigmentation is associated with iron deposition. PMID: 31735009 [PubMed - in process]
Source: Dermatol Online J - Category: Dermatology Authors: Tags: Dermatol Online J Source Type: research
ConclusionsHM are the most frequent non BC SPM in p treated from BC; frequently they are therapy related neoplasms. Deescalating chemotherapy and radiotherapy in BC and finding genetic markers of early malignancy detection are mandatory.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Imatinib with low-dose ara-c can be considered as a potential first-line treatment option for CML-CP.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 25 May 2019Source: Leukemia Research ReportsAuthor(s): Jihane Belkhair, Abderahim Raissi, Hicham Elyahyaoui, Mustapha Ait Ameur, Mohamed ChakourAbstractAtypical chronic myeloid leukemia (aCML), BCR-ABL1 negative is a rare myelodysplastic syndrome /myeloproliferative neoplasm for which no current standard of care exists. The blood smear of patients with aCML showed prominent immature granulocytosis, and granulocytic dysplasia. We admitted a 58-year-old man with splenomegaly, hyperleukocytosis, anemia, and thrombocytopenia; then cytology, cytogenetic and molecular biology analysis of bone m...
Source: Leukemia Research Reports - Category: Hematology Source Type: research
Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research
More News: Anemia | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Research